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【Abstract】Objective:    To investigate the efficacy
and safety of polyethylene glycol 4000 (Forlax®) on adult
patients with functional constipation due to posttraumatic
confinement to bed.
Methods:    A total of 201 posttraumatic bedridden pa-
tients were studied in this prospective, open-labeled, single-
group study. Polyethylene glycol 4000 was administered
orally for 14 days and the dosage was adjusted according
to the Bristol stool types. Demographic characteristics, dis-
ease status, treatment period and factors affecting clinical
outcome, especially the concomitant medications, were
recorded.
Results:    After administration of polyethylene glycol
4000, 194 cases (96.52%) showed remission of constipation,
including 153 (76.12%) persistent remission. The average
defecation frequency increased significantly after treatment
and the percentage of patients with stools of normal types
(Bristol types 3-5) increased as well. Genders, ages and con-
comitant medications showed no significant influence on
the persistent remission rate. After consecutive treatment
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for two weeks, patients with slight movement showed a
significantly higher remission rate than those without move-
ment (95% vs 80%). At the end of treatment, most accompa-
nying symptoms were relieved obviously. Patients with a
medical history of constipation or ever taking laxatives
showed a lower remission rate. Sixty cases (29.85%) devel-
oped diarrhea during the observational period, among whom
6 (10%) withdrew from the clinical observation voluntarily
at the first onset of diarrhea. Two cases suffered from ab-
dominal pain.
Conclusions:    Polyethylene glycol 4000 (Forlax®) has
efficacy on functional constipation in posttraumatic bed-
ridden patients. Furthermore, patients with milder symptoms,
more movement in bed, and longer duration of treatment
but without accompanying symptoms can achieve a higher
remission rate.
Key words:     Polyethylene glycols; Wounds and
injuries; Bed rest; Constipation; Therapeutics
Constipation is one of the most common chronicgastrointestinal problems. The estimated in-cidence of constipation in the United States
is 3% to 19% in general population.1,2 Patients with head
injuries, spinal cord injuries, pelvic fractures, lower ex-
tremity fractures or multiple traumas require a long-term
bed rest, during which the incidence of constipation
reached as high as 50%.3,4 Constipation always brings
inconvenience and tremendous suffering to patients and
strongly influences the recovery from primary disease.
Irritants or lubricants can relieve the symptoms, but
long-term application of them may lead to side effects
like melanosis coli5 and cathartic colon6. The absorp-
tion of fat soluble vitamins is also affected.7 Polyethyl-
ene glycol 4000 (trade name: Forlax®), a long chain
polymer with a high molecular weight, can conjugate
with water molecule through hydrogen bond to increase
the water content and volume of stools, thereby, facili-
tate bowel movement and defecation.8,9 It is neither ab-
sorbed nor metabolized in the digestive tract, hence it
is highly safe and well tolerable. Thus, long-term medi-
cation of polyethylene glycol 4000 is conducive to the
reconstruction of normal defecation pattern. Therefore,
polyethylene glycol 4000 is now being widely used as the
mainstay adult chronic functional constipation
management.10,11 The aim of this study was to verify the
efficacy and safety of polyethylene glycol 4000 on adult
functional constipation of posttraumatic bedridden
patients.
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METHODS
Patients
 A total of 201 posttraumatic patients in bed rest
admitted to the Department of Traumatic Surgery, Re-
search Institute of Surgery, Daping Hospital, Third Mili-
tary Medical University between May 2007 and Sep-
tember 2008, who received the treatment of polyethyl-
ene glycol 4000, were included in this prospective, open-
labeled, single-group, single-center study. There were
143 males (71.14%) and 58 females (28.86%), aged
18-75 years including 141 younger than 50 years, mean
43.29 years. Among them, 24 (11.94%) had a history
of constipation and 9 (4.48%) had ever received laxa-
tives for treating constipation. Of the 201 posttraumatic
bedridden patients, 104 had lower extremity fractures,
55 spinal fractures (including 4 with paraplegia), 13
pelvic fractures and 29 chest or head injuries. Among
the 104 patients with lower extremity fractures, 100 had
received internal or external fixation surgeries and 4
had taken plaster external fixation. Totally, there were
140 cases (69.65%) unable to move voluntarily, 61 (30.35%)
able to move slightly on their beds, and 123 (61.19%) hav-
ing taken drugs likely to cause constipation during the
bedridden period. During one week before treatment, 98
patients (48.76%) had one defecation, 63 (31.34%) twice,
22 (10.95%) three times and 18 (8.96%) more than three
times. Stools of all patients were classified into Bristol
types 1-4 and the patients’ number of each type was
91 (45.27%), 53 (26.37%), 40 (19.90%) and 17 (8.46%).
Inclusion and exclusion criteria
Written informed consents of patients were obtained
and documented before their participation in the trial.
Patients were included in this trial according to the fol-
lowing criteria: (1) age between 18 and 75 years irre-
spective of genders; (2) being bedridden and unable to
defecate on bedside or toilet for more than 1 week; (3)
having returned to a normal diet for at least 5 days; (4)
with an expected bed-ridden duration more than 2
weeks; and (5) having presented with at least one of
the symptoms for more than 3 days (hard and lumpy
stools in Bristol types 1-2, hand-assisted defecation, no
defecation in consecutive 3 days or less than 3 times
of defecation in the past week).
Patients were excluded from this trial if they met
any of the following criteria: (1) nothing by mouth (NPO)
patients; (2) with dysphagia, severe hepatic or renal
dysfunctions; (3) having abdominal surgeries in recent
6 months; (4) allergic to polyethylene glycol 4000; (5)
with organic intestinal diseases such as colorectal
tumor, inflammatory bowel disease, polypus, diverti-
culum, hypogenesis or malformation identified by his-
tory of present illness, physical examination or other
examinations; and (6) taking other laxatives.
Drug and dosage
Polyethylene glycol 4000 (Forlax®, 10 g/sachet)
manufactured by Beaufour Ipsen Industrie (Dreux,
France) was given orally for 14 consecutive days and
the dosage was adjusted according to the Bristol stool
classification as follows: (1) Bristol types 1-2, 20 g for
4 times a day; (2) Bristol types 3-5, 10 g for 4 times a
day; (3) Bristol types 6-7, discontinuation of treatment
for 24 hours; and (4) those with no defecations in the
past 24 hours, continuation of treatment with the same
dosage as the previous day.
Endpoints of the treatment were: (1) completion of
the 14-day treatment, or (2) more than 3 times of de-
fecation per day for consecutive 2 days or stools of Bristol
types 6-7.
Outcome assessment
Recruitment and completion status, demographic
data, disease conditions, treatment duration, achieve-
ment of the endpoint or not, and slight movement in
bed or not were all documented. Concomitant medica-
tions were also recorded accurately, especially those
likely to cause constipation, such as opioid analgesics,
antipsychotic drugs, anticonvulsants, calcium channel
blockers, anticholinergics, dopamine analogues and bile
salts binders.
There are three main indexes in this study to evalu-
ate the therapeutic effects of polyethylene glycol 4000.
(1) Constipation remission, which was described by the
remission and persistent remission rate, remission
duration, time of the first remission, and restoration of
normal defecation pattern. The proportion of patients
achieved constipation remission for more than 3 days
with 1-2 times of defecation/day and stools of Bristol
types 3-5 was recorded. The persistent remission rates
of patients with stools of Bristol types 1-2, less than 3
times of defecation/week before treatment and hand-
assisted defecation at the first day of treatment were
calculated. We comparied the persistent remission rates
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among patients with different ages, genders, concomi-
tant medications and accompanying symptoms at dif-
ferent time points. (2) Accompanying symptoms, which
were described by incidence of accompanying symp-
toms at the beginning of treatment and the end of the
first or second weeks. And (3) adverse effects such as
diarrhea and abdominal pain. The conditions of diar-
rhea were also described, including the onset of diarrhea,
withdrawl from the observation due to diarrhea, and di-
arrhea when withdrawing from the study. Persistent
Remission was defined as 1-2 times of defecation per
day with Bristol type≥3 in 3 consecutive days during
the 14-day treatment period.
Statistical analysis
All subjects were included in a full analysis set
(FAS). Descriptions of the numerical variables included
sample size, mean, standard deviation, median, maxi-
mum and minimum values. And descriptions of categori-
cal variables included the number and percentage of
cases falling into various categories. The statistical
analysis was bilateral and data were recognized statis-
tically significant when P<0.05. By means of cochran-
Mantel-Haenszel (CMH) test, comparison was per-
formed on the persistent remission rates of different
genders. The same method was also used to compare
the persistent remission rates of patients with different
ages, Bristol types before medication, history of con-
stipation and laxative medications, concomitant medi-
cations and accompanying symptoms respectively,
also the efficacy of polyethylene glycol 4000 and medi-
cation for subsequent treatment.
RESULTS
Efficacy
Totally, 171 cases (85.07%) finally reached the treat-
ment endpoint, among whom 127 (63.18%) received
the polyethylene glycol 4000 treatment for 14 days and
the rest (44 cases) had more than 3 times of defeca-
tion in 2 consecutive days or with stools of Bristol types
6-7. The other 30 cases (14.93%) failed to reach the
treatment endpoint due to various reasons. The mean
duration of polyethylene glycol 4000 therapy was (11.81
±3.26) days. In this clinical observation, 35 patiens with-
drew in the first week and 39 in the second week.
 After the administration of polyethylene glycol 4000,
194 patients (96.52%) showed a constipation remission.
The first remission occurred (3.65±2.22) days after treat-
ment and 153 cases (76.12%) achieved a persistent
remission. Patients with less than 3 times of defeca-
tion in one week before treatment had a remission rate
of 74.86%. Patients with Bristol stool types 1-2 and
hand-assisted defecation showed a remission rate of
72.92% and 100%, respectively. Seventy-five cases
(37.31%) restored a normal defecation pattern after
discontinuation of the drug. Only 7 cases (3.48%)
showed no improvement at all. The bowel movements
increased significantly after treatment (Figure 1). The
percentage for patients with stools of Bristol types 1-2
decreased significantly, while that for patients with stools
of Bristol types 3-5 increased (Figure 2). The persis-
tent remission rate was 45.71% for patients taking medi-
cations for less than one week, and 85.04% for those
taking medications for 2 weeks. Genders (χ 2=0.46,
P=0.4992), ages (χ2=0.93, P=0.3341) and concomi-
tant medications (χ2=0.22, P=0.6411) showed no con-
siderable impact on the persistent remission rate. After
two weeks of consecutive treatment, the remission rate
was 95.00% for patients who could move slightly on
the bed, and 80.46% for those unable to move (Table 1).
The remission rate was 78.95% for patients who had
reached the treatment endpoint, while 60.00% for those
failed (χ2=5.04, P=0.0248, Table 2).
Concomitant symptoms of constipation
In this study, 36 cases (17.91%) had accompany-
ing symptoms before treatment, including 22 (10.95%)
with abdominal pain, 13 (6.47%) with difficult defecation,
6 (2.99%) with anorexia and 1 (0.50%) with hand-as-
sisted defecation. At the end of treatment, most symp-
toms were relieved significantly, with a 100% remis-
sion rate in patients with difficult defecation or anorexia.
But the hand-assisted defecation and abdominal pain
in 3 cases (1.49%) remained.
Adverse effects
Totally, 60 patients (29.85%) developed diarrhea,
among whom 6 (10%) withdrew from the clinical obser-
vation at the first onset of diarrhea, and 43 (71.67%)
stayed until the end. Only 2 cases complained of ab-
dominal pain during the treatment, one relieved sponta-
neously and the other relieved after drug discontinuation.
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 DISCUSSION
Pathogenesis of constipation of posttraumatic bed-
ridden patients
Of the 201 patients in our study, the number of male
patients was more than that of female patients and the
mean age was less than 50 years, for trauma frequently
happens to young adults, which is significantly differ-
ent from the demographic characteristics of population
with chronic constipation. Besides, patients with a his-
tory of constipation only accounted for 11.94%, and
most of them developed constipation after confinement
to bed. Mostafa12 has reported an incidence of consti-
pation as high as 83% in 48 cases of critically ill pa-
tients with a normal diet, which also demonstrates that
confinement to bed is an important factor for the devel-
opment of constipation. Causes of confinement to bed
after trauma in this study included lower extremity frac-
tures (51.74%), spinal cord fractures (27.63%), pelvic
fractures (6.47%) and so on. Other possible mecha-
nisms of constipation in such cases were listed as
follows: (1) inappropriate dietary habits, malabsorption
resulting from blood loss and pain during posttraumatic
period, or dehydration3 caused by decreased fiber in-
take and inadequate water intake; (2) psychological
problems or psychiatric disorders such as anxiety and
depression as a result of incapacitated self-care and
defecation in need of others’ help especially; (3) changes
of the living environment or being unaccustomed to def-
ecating in bed in a lying position; (4) application of medi-
cations that may cause constipation; and (5) decreased
activity12 due to absolute bedridden status. As a result
of trauma and surgery, 69.65% cases in the study were
unable to move voluntarily and 30.35% could only move
slightly on the bed. In this study, 61.19% of the cases
took drugs possibly causing constipation, such as pro-
ton pump inhibitor (PPI), calcium channel blocker, anti-
biotics, especially analgesics which can suppress bowel
movements and was significantly associated with
constipation.13
Treatment of constipation of posttraumatic bedrid-
den patients
The treatment of constipation should aim at curing
the primary disease and adjusting patients’ dietary struc-
ture and life habits. Appropriate medications should be
considered to relieve constipation symptoms guided by
the principle that only drugs with minimum toxicity, side
effects and drug dependence, such as leavening agents
Figure 2. Changes in the stool consistency after treatment with
polyethylene glycol 4000.
 Table 2. Remission rates of 201 patients who reached
or failed to reach the treatment endpoint (n, %)
Treatment duration
≤1 week       1-2 weeks       2 weeks
Treatment  Persistent
endpoint     remission
Reached
Failed
Yes
No
Subtotal
Yes
No
Subtotal
  8 (44.44)
10 (55.56)
  18 (100.00)
  8 (47.06)
  9 (52.94)
  17 (100.00)
19 (73.08)
  7 (26.92)
26 (100.00)
10 (76.92)
  3 (23.08)
13 (100.00)
108 (85.04)
  19 (14.96)
127 (100.00)
  0 (0.00)
    0 (0.00)
    0 (0.00)
CMH test: mean value (one-way ordinal)=18.04, P=0.0000.
Table 1. Remission rates of 201 patients with different
bedridden levels (n, %)
Degree of    Persistent
movement    remission
Rare
Slight
Yes
No
Subtotal
Yes
No
Subtotal
10 (43.48)
13 (56.52)
  23 (100.00)
  6 (50.00)
  6 (50.00)
  12 (100.00)
22 (73.33)
  8 (26.67)
  30 (100.00)
  7 (77.78)
  2 (22.22)
     9 (100.00)
70 (80.46)
17 (19.54)
  87 (100.00)
38 (95.00)
  2 (5.00)
  40 (100.00)
Treatment duration
  ≤1 week      1-2 weeks        2 weeks
CMH test: mean value (one-way ordinal)=22.39, P=0.0000.
Figure 1. Changes of defecation frequency after treatment with
polyethylene glycol 4000.
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and osmotic laxatives could be chosen. For patients
with fecal impaction, symptoms should be first relieved
by cleaning enema, or short-term administration of irri-
tants before the application of leavening agents or os-
motic laxatives. For those with constipations caused
by long-term bedridden status, stimulants or lubricants
could be used to relieve the short-term symptoms.
However, constipation may relapse due to persistent
existence of inducing factors. Repeated use may
weaken the effectiveness of the above laxatives and
result in anorectal burning. The use of irritants may
cause abdominal cramp; a long-term use may lead to
melanosis coli5 and cathartic colon6 and affect the ab-
sorption of fat soluble vitamins.7 In some severe cases,
water and electrolyte disorders may be arised, thereby
affecting the recovery of patients. Therefore, the first-
line treatments for constipation of bedridden patients
should be osmotic and bulk forming laxatives, with the
treatment goal set as one or two times of defecation
per day.3
Polyethylene glycol 4000 (Forlax®), a long chain
polymer with a high molecular weight, can conjugate
with water molecule through hydrogen bond to increase
the water content and volume of stools, thereby, facili-
tate bowel movement and defecation.8,9 It is neither
absorbed nor metabolized in the digestive tract, hence
it is highly safe and well tolerable. Thus, the long-term
medication is conducive to reconstruct the normal def-
ecation pattern of patients, and has now been widely
used for adult chronic functional constipation.10,14 It has
been reported to be more effective than lactulose15 and
safer than Tegaserod16.
Of the 201 patients treated with polyethylene glycol
4000, 194 (94.52%) showed remission of constipation,
in whom 153 (76.12%) showed persistent remission
and 75 (37.31%) restored their normal defecation pat-
tern with standard treatment, indicating the efficacy of
polyethylene glycol 4000 (Forlax®) on such constipation
patients. Meanwhile, 91 cases who had accompanying
symptoms such as abdominal pain, difficult defecation,
feeling of incomplete evacuation and anorexia showed
a significant relief at the end of treatment. The genders,
ages, concomitant medications and types of trauma
showed no significant influence on the persistent re-
mission rate. Factors that influenced the therapeutic
effects included severity of constipation, duration of
treatment, situation of accompanying symptoms, his-
tory of constipation and ability of slight movement in bed.
Patients with milder constipation showed a higher
remission rate. Remission rates for those with less than
three times of defecation per week or stools of Bristol
types 1-2 before treatment were 74.86% and 72.92%
respectively, which were significantly lower than the to-
tal remission rate of this group (76.12%). The persistent
remission rate of patients with Bristol types 1-2 after the
2-week treatment was 81.18%, lower than that of those
with Bristol types 3-5 (92.86%). The persistent remis-
sion rate increased with the prolongation of treatment.
The remission rate was 85% for patients completing the
2-week treatment, while 78.95% for those reached the
treatmen endpoint, as polyethylene glycol 4000 is an
osmotic laxative and needs a long-term administration
to keep the normal bowel movement. Patients without
accompanying symptoms had a higher remission rate.
Patients with a history of constipation and laxative medi-
cation had a poorer remission rate. Patients who could
move slightly in bed showed a remission rate as high
as 95% at the end of the second week, indicating that
an appropriate movement in bed should be advocated.
Adverse drug reactions of polyethylene glycol 4000
include abdominal distension, abdominal pain, diarrhea
and nausea.17 During the treatment with polyethylene
glycol 4000, 60 cases (29.85%) developed diarrhea as-
sociated with drug administration at different dosages.
This indicates that it is necessary to adjust the dosage
promptly and individually according to different responses
to drugs in order to ensure the overall efficacy of the
drug. Only 2 patients complained of an abdominal pain,
which was resolved spontaneously or after discontinu-
ation of treatment. No allergic reaction was reported in
this trial, consistent with other studies17,18. Our study
shows the excellent safety of polyethylene glycol 4000
among posttraumatic bedridden patients.
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